Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**DSP-1083** is an investigational cell therapy for Parkinson’s disease composed of human induced pluripotent stem cell (iPSC)-derived dopaminergic progenitor cells. The primary mechanism is to restore dopaminergic neuronal function by implantation of dopamine neural progenitors, which secrete dopamine, aiming to ameliorate neurological symptoms of Parkinson’s disease. The therapy is currently under clinical development, with safety, tolerability, and efficacy being assessed in a first-in-human, multicenter trial. The sponsor and primary developer is Sumitomo Pharma America. Clinical administration involves stereotactic implantation into the brain[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DSP-1083.